로딩 중...
52주 최고가 대비 67.1% 위치
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
SEC 13F 공시 기준 · 2025-Q3
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $983.7M | $1.09B | $1.10B | $1.19B |
| 영업이익 | - | $192.4M | $200.7M | $161.1M | $198.8M |
| 당기순이익 | - | $142.8M | $145.6M | $117.8M | $139.8M |
| 잉여현금흐름 (FCF) | - | $-139.8M | $-336.7M | $-157.8M | $11.0M |
| 수익성 비율 | |||||
| 영업이익률 | - | 19.6% | 18.5% | 14.6% | 16.8% |
| 순이익률 | - | 14.5% | 13.4% | 10.7% | 11.8% |
| ROE (자기자본이익률) | - | 14.3% | 12.9% | 8.4% | 9.4% |
| ROA (자산이익률) | - | 8.6% | 7.0% | 5.1% | 5.5% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 10.3% | 1.7% | 7.4% |
| EPS 성장률 (YoY) | - | - | 1.9% | -21.8% | 18.6% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 36.2x | 57.4x | 52.0x | 30.5x |
| PBR (주가순자산배수) | - | 1.0x | 1.4x | 0.8x | 0.5x |
| PSR (주가매출배수) | - | 1.0x | 1.4x | 1.0x | 0.7x |
| FCF Yield | - | -14.4% | -21.5% | -14.2% | 1.4% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.22 | 0.35 | 0.31 | 0.32 |
| 유동비율 | - | 1.83 | 1.50 | 1.84 | 1.76 |
MOLINA HEALTHCARE INC
$179.86
$9.4B